Olink® to Science
The Olink to Science blog aims to inform, inspire, and support you in all things proteomics. Subscribe to stay updated on the latest proteomics research, ideas, and technological developments.
A five-year old child infected by SARS-CoV-2 developed severe symptoms of arthralgia (joint pain) and thromobocytopenia (abnormally low platelet count), revealing significant dysregulation of their immune system. This condition, called Haploinsufficiency of Suppressor of Cytokine Signaling (SOCS1) is accompanied by excessive B-cell activity, an increase of a type of white blood cell called eosinophils, and high levels of IgE antibodies. The Olink® Target 48 Cytokine panel was used to confirm up-regulation of multiple interferon (IFN)-inducible genes, comparable to dysregulation observed in systemic lupus erythematosus (SLE).
Alzheimer’s Disease (AD) is a devastating neurodegenerative disorder affecting nearly 50 million worldwide; with only 1-in-4 people diagnosed there is a genuine need for discovery of blood-based biomarkers. A recent paper from a group at Harvard and Massachusetts General Hospital looks at a technical evaluation of reproducibility and biological variation in AD patient samples collected over time.
The biological process of a cytokine release storm is a generalized inflammatory response to a pathogen (most recently associated with COVID-19 mortality), or a reaction to a cell-therapy treatment or autoimmune disease (such as primary hemophagocytic lymphohistiocytosis, a severe systemic inflammatory syndrome). Described here are the interaction between the triggered driver cells (both adaptive T-cells and antigen-presenting cells) and the important cytokine players involved (including IL-18, TNF, IL-1b, IFN-gamma, IL-6 and IL-17)
Olink panels targeting inflammation-related proteins suggest new pathophysiological mechanisms across diverse disease areas. This brief review shows how cytokines, chemokines and other immune- and inflammatory proteins are integrally involved with infectious disease (COVID-19 response), neurology (traumatic brain injury), digestive disorders (ulcerative colitis) and skin disease (atopic dermatitis).e and leading to major changes across tissues and organs.
Want to learn more?
Here you will find the latest list of publications that have used Olink’s panels for protein biomarker discovery in the reported studies, or which have reviewed our technology. The publications are grouped according to year of publications.
With our in-house experts, digital tools and technical document library, we support you throughout the whole process of running your project, from study design to data interpretation.
Throughout pharmaceutical development and academic/clinical research, Olink provides actionable insights through protein biomarkers across an extensive range of application areas, covering all aspects of human biology in health and disease.
Protein data points generated
Publications listed on website